William Blair Reiterates “Hold” Rating for BioMarin Pharmaceutical (BMRN)
BioMarin Pharmaceutical (NASDAQ:BMRN)‘s stock had its “hold” rating restated by stock analysts at William Blair in a report issued on Wednesday, American Banking & Market News reports. They currently have a $88.00 price target on the stock. William Blair’s price objective would suggest a potential upside of 13.56% from the stock’s previous close.
BioMarin Pharmaceutical (NASDAQ:BMRN) traded up 2.02% on Wednesday, hitting $77.492. 3,191,145 shares of the company’s stock traded hands. BioMarin Pharmaceutical has a 1-year low of $36.28 and a 1-year high of $78.83. The stock’s 50-day moving average is $67.2 and its 200-day moving average is $63.36. The company’s market cap is $10.857 billion.
BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Thursday, July 25th. The company reported ($0.16) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.29) by $0.13. The company had revenue of $136.80 million for the quarter, compared to the consensus estimate of $134.33 million. During the same quarter in the previous year, the company posted ($0.27) earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. Analysts expect that BioMarin Pharmaceutical will post $-1.16 EPS for the current fiscal year.
A number of other firms have also recently commented on BMRN. Analysts at RBC Capital reiterated a “buy” rating on shares of BioMarin Pharmaceutical (NASDAQ:BMRN) in a research note to investors on Wednesday. They now have a $77.00 price target on the stock. Separately, analysts at Stifel Nicolaus downgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN) from a “buy” rating to a “hold” rating in a research note to investors on Wednesday. They now have a $70.00 price target on the stock. They noted that the move was a valuation call. Finally, analysts at Merrill Lynch reiterated a “buy” rating on shares of BioMarin Pharmaceutical (NASDAQ:BMRN) in a research note to investors on Monday.
Eight investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. BioMarin Pharmaceutical currently has an average rating of “Buy” and an average price target of $71.37.
In other BioMarin Pharmaceutical news, CEO Jean Jacques Bienaime sold 2,000 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $73.08, for a total transaction of $146,160.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.